The Chinese medtech market is the third largest in the world, and forecasted to be the second largest worldwide by 2020, with a steady growth in the coming years of more than 10%.
The Chinese local medtech industry has changed its product segment focus in recent years, moving from low-end to the middle portion of the market, stimulated by government initiatives, alterations in reimbursement management and tendering processes.
3 principal drivers are shaping the Chinese healthcare market:
> Healthcare reforms and new regulatory policies
> Shift in the provider landscape
Striking is the role of the Chinese reimbursement landscape, defining and leading to intriguing developments within all the market drivers.
China has a unique and complex reimbursement system, presenting a tricky playing field for those unfamiliar with its mechanisms.
Download this whitepaper to understand the Chinese healthcare system, and use it to optimize your medtech strategy in this high potential market.